First messenger RNA influenza vaccine outperforms standard-dose vaccination
1. mFlusiva is the first messenger RNA influenza vaccine approved in the United States, with the FLUENT phase 3 trial ...
1. mFlusiva is the first messenger RNA influenza vaccine approved in the United States, with the FLUENT phase 3 trial ...
1. The vaccination resulted in adverse events that were grade 2 or lower with no serious adverse events. 2. Serum ...
1. In this phase 1-2 clinical trial, an adenovirus viral vector expressing non-structural hepatitis C proteins was safe in a ...
1. In a large Danish cohort study, the measles-mumps-rubella (MMR) vaccine was not significantly associated with autism. 2. There was ...
1. Surveillance of adverse events after diphtheria-tetanus-acellular pertussis (DTaP) vaccine administration reported to the Vaccine Adverse Event Reporting System (VAERS) ...
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Monthly plan selected: $4.99 /month.
5-day free trial · cancel anytime
Then $4.99/month. Manage renewal in your account.
Yearly plan selected: $49.90 /year.
2 months free · only $4.16/month
Then $49.90/year. Manage renewal in your account.
Already a member? Sign in